Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Athersys Inc (NQ: ATHX )

2.220 USD +0.070 (+3.26%)
Streaming Delayed Price Updated: 7:15 AM EST, Jan 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Athersys Inc

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
38 Stocks Moving in Tuesday's Pre-Market Session
Gainers Koss Corporation (NASDAQ: KOSS) shares rose 69% to $10.17 in pre-market trading. Koss gained around 80% on Monday as the ... 
Tags BB MOTS QUMU
From Benzinga
First Week of March 19th Options Trading For Athersys (ATHX)
Investors in Athersys Inc (ATHX) saw new options become available this week, for the March 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ATHX options... 
Tags Stocks
From Market News Video
The Math Shows XBI Can Go To $186
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Market Briefing For Tuesday, Dec. 22
Big-caps remain extended, as bears continue 'fighting the Fed', even as for sure, a post-Expiration pause would be normal, but Tesla might mix that up. 
Tags Technology Pharma/Biotech Stocks / Equities
From Blogs - TalkMarkets
Why Athersys Stock Jumped Today
The biotech announced the enrollment of the first patient in a key clinical study. 
Tags Market News ATHX
From Motley Fool
4 Best Penny Stocks To Buy Right Now? Analyst Targets Up To 246%
Tags Market News
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
UTHealth in Houston and Athersys Announce Commencement of Patient Enrollment in a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma
UTHealth and Athersys announce patient enrollment in an innovative clinical study of MultiStem® cell therapy for the treatment of traumatic injuries 
From Business Wire News Releases
Market Briefing For Monday, Dec. 21
History is replete with those who tried to make the market go their way at a time when more powerful forces argued otherwise. 
Tags Stocks / Equities Pharma/Biotech
From Blogs - TalkMarkets
4 Penny Stocks To Buy According To Analysts; 48%-463% Price Targets
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
12 Healthcare Stocks Moving In Wednesday's After-Market Session
Gainers Corcept Therapeutics (NASDAQ:CORT) shares rose 22.99% to $22.95 during Wednesday's after-market session. At the close, ... 
Tags AQST ATHX Market News
From Benzinga
Athersys Announces Three Appointments to Board of Directors
Athersys announces three appointments to its board of directors, deepening board expertise to prepare for future growth and commercialization. 
From Business Wire News Releases
Athersys Reports Third Quarter 2020 Results and Provides Corporate Update
Athersys announces Q3 earnings and initiation of MultiStem® Phase 2 clinical trial in patients with trauma related inflammation and complications 
From Business Wire News Releases
The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions
Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a ... 
Tags Penny Stocks RETA MTCR
From Benzinga
Athersys to Host Third Quarter Financial Results Call
Athersys, Inc. (Nasdaq: ATHX) will release its third quarter 2020 financial results on Monday, November 9, 2020. 
From Business Wire News Releases
44 Stocks Moving In Wednesday's Mid-Day Session
Gainers Spi Energy Co Ltd (NASDAQ: SPI) shares climbed 718.5% to $8.43 after the company launched a new electric vehicle ... 
Tags AXU GP NKE
From Benzinga
Return On Capital Employed Overview: Athersys
During Q2, Athersys's (NASDAQ: ATHX) reported sales totaled $84.00 thousand. Despite a 16.36% in earnings, the company posted a loss ... 
Tags ATHX News Earnings
From Benzinga
Thinking about buying stock in Athersys, Party City, AcelRx Pharmaceuticals, Southwest Airlines, or Carnival Corp?
InvestorsObserver issues critical PriceWatch Alerts for ATHX, PRTY, ACRX, LUV, and CCL. 
From PR Newswire
The Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags Offerings GMAB CSTL
From Benzinga
38 Stocks Moving in Wednesday's Pre-Market Session
Gainers Predictive Oncology Inc. (NASDAQ: POAI) shares rose 43.1% to $1.21 in pre-market trading after the company secured ... 
Tags ACET Top Gainers GOGL
From Benzinga
FDA Grants RMAT Designation to MultiStem Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome
MultiStem is the only cell therapy program for acute respiratory distress syndrome (ARDS) that has both Fast Track and RMAT designation from the FDA. 
From Business Wire News Releases
First Week of ATHX November 20th Options Trading
Investors in Athersys Inc (ATHX) saw new options become available this week, for the November 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ATHX options... 
Tags Stocks
From Market News Video
The Math Shows XBI Can Go To $161
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Sum Up The Pieces: VHT Could Be Worth $228
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Athersys (ATHX) Q2 2020 Earnings Call Transcript
ATHX earnings call for the period ending June 30, 2020. 
Tags ATHX Market News
From Motley Fool
Athersys Reports Second Quarter 2020 Results
Athersys has made progress during Q2 in key clinical programs and infrastructure to support its planned transition to becoming a commercial company. 
From Business Wire News Releases
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive ... 
Tags NVAX VBLT CATB
From Benzinga
Block-Buster SAR-CoV2 Disrupters Pre-ICU / Admitted ICU Patient Treatments & COVID-19 T-Cell Vaccine Horizon
In recent months, there has been a flurry of activity within the clinical trial sector. When all trial types are considered, there are over 400 studies exploring approaches to diagnosing, treating, or... 
Tags Healthcare Pharma/Biotech Stocks / Equities
From Blogs - TalkMarkets
Market Briefing For Tuesday, July 21
Tuesday may be a bit skittish but we see this market moving higher even as the case counts do as well; and it's not incongruous as to how this battle rages both for humanity and the weapons to fight... 
Tags Technology Pharma/Biotech Stocks / Equities
From Blogs - TalkMarkets
Athersys to Host Second Quarter Financial Results Call
Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2020 financial results on Monday, August 10, 2020. 
From Business Wire News Releases
First Week of ATHX September 18th Options Trading
Investors in Athersys Inc (ATHX) saw new options begin trading this week, for the September 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ATHX options... 
Tags Stocks
From Market News Video
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.